H.C. Wainwright reiterates Aethlon Medical stock rating at Neutral

Investing.com reports that H.C. Wainwright has reaffirmed its Neutral rating and $1.50 price target for Aethlon Medical (NASDAQ:AEMD). This assessment follows the company's first-quarter fiscal 2027 results and corporate update. As of the current trading price of $2.94, AEMD is considered undervalued relative to its Fair Value, making it an attractive opportunity among potentially undervalued stocks.

On August 13, 2026, Aethlon Medical announced the initiation of Cohort 3 in its Phase 1 solid tumor study in Australia. This trial, which involves three cohorts with different treatment regimens, is the final cohort in the study. The first participant of Cohort 3 has undergone two months of treatment without experiencing any serious adverse events or dose-limiting toxicity.

The company anticipates completing all treatments and the 8-week follow-up period by year-end 2026 or early 2027. Despite its small market cap of $1.39 million and a 95% decline in stock price over the past year, AEMD continues to attract attention due to its progress in clinical trials and effective cost management. Investors are closely monitoring the company's advancements in clinical trials and financial performance.